A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 195 participants.
Also called NCT05432167
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 195 participants
- Sponsor
- Registry
-
NCT05432167
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT05432167. Randomized; double masking; primary purpose treatment. Start 2022-04-29 (actual); primary completion 2024-05-02 (actual). Results posted on 2025-05-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
- Condition
- Uncontrolled Hypertension
- Condition
- Chronic Kidney Diseases
- Intervention (Drug)
- CIN-107
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
- Collaborator
- Parexel
Record details
- Record id
cardio:ct-nct05432167- Content hash
cccdaf52c562a797887a269710bd315f22b638b66fcef1b871df0af47655a63a